EGFR and non-small cell lung carcinoma: Currently, the US Food and Drug Administration (FDA) has approved six EGFR TKIs, as well as a fully humanized monoclonal antibody targeting EGFR, as the standard of care for the first-line treatment of NSCLC patients with EGFR mutations (30).